Karyopharm Therapeutics Inc.
Every calculator, already run for KPTI
Open the full toolkit →You have the numbers on KPTI. Get the argument.
A written report on which of these readings actually decide the outcome for Karyopharm Therapeutics Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering KPTIAnalyst Price Target Disagreement for Karyopharm Therapeutics Inc.
Wall Street's bull case implies +465% from the current price; the bear case implies +54%. A 411% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult…
KPTI — frequently asked
Is KPTI a buy right now?
Wall Street's consensus rating on Karyopharm Therapeutics Inc. is Buy across 6 analysts, with a mean price target of $6.40 (+229% vs. the current $1.95). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Karyopharm Therapeutics Inc.?
Analysts covering Karyopharm Therapeutics Inc. (KPTI) range from a bear-case target of $3.00 to a bull-case high of $11.00, with a mean consensus target of $6.40 across 5 analysts. The spread of $8.00 (411% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Karyopharm Therapeutics Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Karyopharm Therapeutics Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full KPTI research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Karyopharm Therapeutics Inc., in minutes. 3 free reports included with every account — no credit card required.